Journal of Immunotherapy最新文献_第2页

Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study. 接受免疫检查点抑制剂的非小细胞肺癌患者使用二甲双胍与死亡率之间的关系：一项回顾性队列研究

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000565

Xinyi Sun, James Heyward, Joseph C Murray, G Caleb Alexander, Hemalkumar B Mehta

{"title":"Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.","authors":"Xinyi Sun, James Heyward, Joseph C Murray, G Caleb Alexander, Hemalkumar B Mehta","doi":"10.1097/CJI.0000000000000565","DOIUrl":"10.1097/CJI.0000000000000565","url":null,"abstract":"Metformin has the potential to synergistically enhance the effect of immune checkpoint inhibitors (ICI) in nonsmall cell lung cancer (NSCLC). We evaluated the association between metformin use before ICI initiation and cancer-specific and all-cause mortality among NSCLC patients. We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2013-2019), including NSCLC patients with type 2 diabetes who newly initiated ICI therapy and had prior antidiabetic medication use. The exposure was metformin monotherapy versus sulfonylurea and/or dipeptidyl peptidase-4 (DPP-4) inhibitors. The primary outcome was cancer-specific mortality, and the secondary outcome was all-cause mortality. We used stabilized inverse probability of treatment weighting (sIPTW) to adjust for confounders. Fine-Gray competing risk model estimated cancer-specific mortality, while Cox proportional hazards model evaluated all-cause mortality. We included 1123 metformin users and 362 sulfonylurea/DPP-4 users. Although baseline characteristics differed, groups were well balanced after weighting. The adjusted incidence rate (aIR) of cancer-specific mortality was 82 versus 81 (aIR difference=1, 95% CI: -13 to 16), and all-cause mortality was 71 versus 67 (aIR difference=4, 95% CI: -6 to 15) per 100 person-years for metformin and sulfonylurea/DPP-4 users, respectively. Metformin use was not significantly associated with cancer-specific mortality (adjusted hazard ratio (aHR)=1.08, 95% CI: 0.88-1.33) and all-cause mortality (aHR=1.07, 95% CI: 0.90-1.26). In this large, diverse cohort of individuals with NSCLC using ICI, there was no statistically significant association between metformin use and cancer-specific or all-cause mortality.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"273-280"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating Overlapping Immune-related Genetic Markers in Cholangiocarcinoma and Inflammatory Bowel Disease for Predictive Prognosis. 研究胆管癌和炎症性肠病中重叠免疫相关遗传标记的预测预后

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000562

Shuang Zheng, Caizheng Wang, Junhui Fu, Jinfan Shao

{"title":"Investigating Overlapping Immune-related Genetic Markers in Cholangiocarcinoma and Inflammatory Bowel Disease for Predictive Prognosis.","authors":"Shuang Zheng, Caizheng Wang, Junhui Fu, Jinfan Shao","doi":"10.1097/CJI.0000000000000562","DOIUrl":"10.1097/CJI.0000000000000562","url":null,"abstract":"This study aims to explore the common immune-related gene characteristics of cholangiocarcinoma (CHOL) and inflammatory bowel disease (IBD) to predict disease prognosis. By analyzing the gene expression data from the TCGA, GEO, and NGDC databases, differentially expressed immune-related genes (DE-IRGs) were screened, and a prognostic model was constructed. The results showed that CCR7, OSM, S100P, ACVR1C, OSMR, SPP1, and PIK3R3 were key immune-related genes, and their expressions were closely related to the occurrence and development of CHOL and IBD. Patients in the low immune risk score (IRS) group had more abundant antitumor immune cell infiltration, while those in the high IRS group had more macrophage infiltration. In addition, the model based on these genes had good predictive ability for the diagnosis and prognosis of CHOL and IBD, with an area under the ROC curve (AUC) value exceeding 0.7. This study also predicted potential small molecule drugs that might be effective for the treatment of CHOL, such as Umbralisib and Tamoxifen. In conclusion, this study provides new biomarkers and potential targets for diagnosis, prognosis assessment, and treatment of CHOL and IBD.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"258-272"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CSF1-CAR Specifically Targets CSF1R + Pancreatic Cancer Cells and Tumor-Associated Macrophages. CSF1-CAR特异性靶向CSF1R+胰腺癌细胞和肿瘤相关巨噬细胞

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000563

Yongjie Zhu, Ruipu Sun, Jiawei Fan, Haiyan Ma, Bin Sun

引用次数: 0

Harnessing Calmodulin-Related Genes to Build a Prognostic Model in Esophageal Squamous Cell Carcinoma for a Comprehensive Analysis of Single-Cell Immune Characteristics and Drug Efficacy. 利用钙调素相关基因构建食管鳞状细胞癌预后模型，综合分析单细胞免疫特性和药物疗效。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-09-01 DOI: 10.1097/CJI.0000000000000561

Shasha Cao, Shumin Lun, Lijuan Duan, Zhaowei Gao, Xiaoxiao Wang, Yutong Li, Yaowen Zhang

{"title":"Harnessing Calmodulin-Related Genes to Build a Prognostic Model in Esophageal Squamous Cell Carcinoma for a Comprehensive Analysis of Single-Cell Immune Characteristics and Drug Efficacy.","authors":"Shasha Cao, Shumin Lun, Lijuan Duan, Zhaowei Gao, Xiaoxiao Wang, Yutong Li, Yaowen Zhang","doi":"10.1097/CJI.0000000000000561","DOIUrl":"10.1097/CJI.0000000000000561","url":null,"abstract":"Calmodulin (CALM) has a bearing on the prognosis of various cancers. However, the prognostic value of CALM in esophageal squamous cell carcinoma (ESCC) remains unelucidated. Differentially expressed genes (DEGs) were screened between normal and tumor groups of TCGA-ESCC sets. The intersection of DEGs with calmodulin-related genes (CRGs) yielded differentially expressed CRGs (DE-CRGs). A prognostic model was established using LASSO Cox regression analysis and multivariate Cox regression analysis. qPCR validated the expression of prognostic feature genes. Analysis of gene expression patterns of different cellular clusters was based on single-cell sequencing data. Lastly, GSEA enrichment, immune infiltration, mutational profiling, drug sensitivity, and molecular docking as well as cellular thermal shift assay (CETSA) were conducted for ESCC patients. A prognosis model with excellent predictive capability was created based on 4 feature genes (ATP2B3, CALB1, KCNQ1, and MYO1G). The qPCR results demonstrated that ATP2B3 and KCNQ1 were significantly downregulated in human ESCC cells, whereas CALB1 and MYO1G were upregulated ( P <0.05). Single-cell analysis uncovered that MYO1G and KCNQ1 were mainly expressed in different cell clusters. Furthermore, this risk model was strongly associated with functional pathway enrichment, immune cell infiltration, and somatic mutations. We also identified AZD-8055 may be potential therapy for ESCC patients. The CETSA experiment demonstrated the existence of a favorable binding thermal stability between AZD-8055 and MYO1G. This research may identify potential biomarkers for predicting the prognosis of ESCC patients.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"244-257"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wild-Type p53 Overexpression Inhibits DNA Damage Pathways and Reduces PD-L1 Expression in Prostate Cancer. 野生型p53过表达抑制DNA损伤途径并降低前列腺癌中PD-L1的表达。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-08-12 DOI: 10.1097/CJI.0000000000000573

Heng Zhang, Guojun Lu, Yang Hu, Qing Yang, Jiawei Jiang, Min Xu

{"title":"Wild-Type p53 Overexpression Inhibits DNA Damage Pathways and Reduces PD-L1 Expression in Prostate Cancer.","authors":"Heng Zhang, Guojun Lu, Yang Hu, Qing Yang, Jiawei Jiang, Min Xu","doi":"10.1097/CJI.0000000000000573","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000573","url":null,"abstract":"The DNA damage response (DDR) pathway is crucial in tumor development and metastasis, influencing the tumor microenvironment. This study explores how p53, encoded by TP53, regulates PD-L1 expression in prostate cancer (PCa) from clinical, cellular, and tissue perspectives. Clinical PCa samples were analyzed for PD-L1, PD-1, p53, and PARP1 protein expression. DU145 cells were transfected with plasmids to overexpress wild-type p53 (WT-p53) and PD-L1. Protein and mRNA levels were measured by western blotting and qRT-PCR. DNA damage was assessed by γH2AX staining and comet assays. Cell proliferation was evaluated by colony formation assays, and apoptosis was analyzed by flow cytometry. A mouse tumor model was established to monitor tumor growth. Protein levels, γH2AX, and DNA damage were measured in mouse tumor tissues. Analysis of clinical samples showed a significant negative correlation between p53 and PD-L1/PARP1 levels. In vitro and in vivo experiments confirmed that WT-p53 overexpression reduces γH2AX expression, inhibiting DDR pathway activation. This led to decreased PARP1 and PD-L1 expression, increased apoptosis, and suppressed PCa cell proliferation. This study demonstrates that WT-p53 inhibits the activation of the DDR pathway, thereby leading to the downregulation of PARP1 and PD-L1 protein expression. These findings provide a novel theoretical foundation and potential therapeutic targets for future PCa treatments and research.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma. 一种具有TLR 7/8、STING和炎性体活性的新型咪唑喹啉在小鼠黑色素瘤和新驱动的乳腺腺癌中显示出抗肿瘤功效。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2025-08-06 DOI: 10.1097/CJI.0000000000000571

Shubhmita Bhatnagar, Vishnu Revuri, Carmen Merali, Bingxin Wang, John R Schultz, Peter Larson, Daohai Yu, Swayam Prabha, Thomas S Griffith, David Ferguson, Salim Merali, Jayanth Panyam

{"title":"A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma.","authors":"Shubhmita Bhatnagar, Vishnu Revuri, Carmen Merali, Bingxin Wang, John R Schultz, Peter Larson, Daohai Yu, Swayam Prabha, Thomas S Griffith, David Ferguson, Salim Merali, Jayanth Panyam","doi":"10.1097/CJI.0000000000000571","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000571","url":null,"abstract":"Activation of endosomal Toll-like receptors 7 and 8 in antigen-presenting cells typically results in the induction of type I interferons (IFN). We previously reported a series of imidazoquinolines that potently activate TLR7/8. The potency and selectivity of these compounds can be tuned via substitutions to the N1 and C2 positions of the tricycle. Furthermore, C2-alkyl substitutions that project into a hydrophobic pocket at the dimer interface of the receptor significantly affect TLR7 and TLR8 activities. In the current study, we show that these compounds induce the expression of IFN-γ, a type II IFN, in addition to the classic type I IFNs. To understand the mechanism of type II IFN induction, we utilized global proteomics to evaluate the effect of our lead TLR7/8 agonist 4-amino-1-(4-(aminomethyl)benzyl)-2-butyl-7-methoxycarbonyl-1H-imidazo[4,5-c]quinoline (558) on dendritic cells (DCs). These studies show 558 activated STING and inflammasome pathways, in addition to its effect on TLR7/8. Based on the multifactorial mechanism of action, we also investigated the therapeutic benefit of 558 as a single agent. The effect of 558 dosing on various immune cell populations was investigated in tumor-bearing and healthy mice. Further, the effect of 558 on tumor multiplicity and tumor burden was studied in the transgenic Balb-neuT mice, which develop neu-driven mammary adenocarcinomas. 558 reversed the tumor-induced declines in antitumor immune cells in the bone marrow and lymph nodes of tumor-bearing mice. In vivo studies showed that 558 significantly reduced the rate of tumor growth, likely due to enhanced DC activation in the lymph nodes and CD8 T cell infiltration into the tumor tissue.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative Multi-Omics Analysis Reveals Molecular Subtypes of Ovarian Cancer and Constructs Prognostic Models. 综合多组学分析揭示卵巢癌分子亚型并构建预后模型。

IF 3.2 4区医学

Journal of Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-04-09 DOI: 10.1097/CJI.0000000000000557

Min Zhou, Jie Pi, Yuzi Zhao

{"title":"Integrative Multi-Omics Analysis Reveals Molecular Subtypes of Ovarian Cancer and Constructs Prognostic Models.","authors":"Min Zhou, Jie Pi, Yuzi Zhao","doi":"10.1097/CJI.0000000000000557","DOIUrl":"10.1097/CJI.0000000000000557","url":null,"abstract":"Abstract: Ovarian cancer (OV) remains the most lethal gynecological malignancy. The aim of this study was to identify molecular subtypes of OV through integrative multi-omics analysis and construct machine learning-based prognostic models for predicting the efficacy of immunotherapy. In here, the mutation, copy number variation, RNA sequencing expression profiles, and clinical information were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Multi-omics data were stratified using the MOVICS package, identifying different molecular subtypes. Our analysis identified 2 molecular subtypes (CS1 and CS2) with significant survival differences. Transcriptional regulatory network analysis revealed differential activation of transcription factors such as FOXA1 and GATA3 in CS1, whereas AR and ESR2 were enriched in CS2. A robust prognostic signature comprising 5 key genes was developed through the integration of 10 machine learning algorithms, demonstrating high predictive power across data sets. Immune cell infiltration analysis revealed that anti-tumor immune cells were more abundant in low-risk groups, whereas pro-tumor immune cells predominated in high-risk groups. Furthermore, low-risk patients exhibited better immunotherapy responses and higher tumor mutational burden (TMB). In conclusion, our findings underscore the potential of multi-omics integration in unveiling novel OV subtypes and constructing predictive models that inform personalized treatment strategies. Future research should focus on validating these findings in larger cohorts to enhance OV management through targeted therapeutic approaches.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"197-208"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual Roles of EZH2 in Tumor Proliferation and Immune Evasion in Lung Squamous Cell Carcinoma: A Pathway to Novel Immunotherapeutic Approaches. EZH2在肺鳞状细胞癌的肿瘤增殖和免疫逃避中的双重作用：一种新的免疫治疗途径

IF 3.2 4区医学

Journal of Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-06-04 DOI: 10.1097/CJI.0000000000000560

Ling Xu, Chun Ye, Shuihong Yu

{"title":"Dual Roles of EZH2 in Tumor Proliferation and Immune Evasion in Lung Squamous Cell Carcinoma: A Pathway to Novel Immunotherapeutic Approaches.","authors":"Ling Xu, Chun Ye, Shuihong Yu","doi":"10.1097/CJI.0000000000000560","DOIUrl":"https://doi.org/10.1097/CJI.0000000000000560","url":null,"abstract":"Abstract: Lung squamous cell carcinoma (LUSC) remains a major clinical challenge due to its aggressive nature and poor prognosis. Enhancer of zeste homolog 2 (EZH2), a key epigenetic regulator within the polycomb repressive complex 2 (PRC2), has emerged as a critical player in cancer progression. This study investigates the dual role of EZH2 in driving tumor proliferation and modulating the immune microenvironment in LUSC. Bioinformatics analysis revealed significant upregulation of EZH2 in LUSC tissues compared with normal counterparts, with high EZH2 expression correlating with improved overall survival in early-stage patients. Functional assays in EZH2 knockout LUSC cell lines demonstrated reduced tumor cell proliferation, migration, and invasion alongside enhanced apoptosis and cell cycle arrest. Furthermore, in vivo studies using an EZH2 knockout mouse model showed decreased tumor growth and increased immune cell infiltration, including CD8+ T cells, macrophages, and neutrophils. These findings highlight the pivotal role of EZH2 in promoting tumor progression and orchestrating immune evasion mechanisms in LUSC. Given its multifaceted influence on tumor biology and the immune landscape, EZH2 represents a promising therapeutic target for improving outcomes in LUSC patients. Future studies should explore the therapeutic potential of targeting EZH2 to enhance immune responses and overcome resistance to current treatments.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":"48 6","pages":"221-230"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Antibiotics on First-line Immunotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. 抗生素对鼻咽癌复发或转移患者一线免疫治疗的影响。

IF 3.2 4区医学

Journal of Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-04-10 DOI: 10.1097/CJI.0000000000000556

Yuting Fang, Binhao Wu, Rong Zhang, Xiaozhong Chen, Feng Jiang, Qifeng Jin, Ting Jin, Shuang Huang, Changjuan Tao, Mengyun Qiang, Yongfeng Piao, Yonghong Hua, Xinglai Feng, Caineng Cao

{"title":"Effects of Antibiotics on First-line Immunotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma.","authors":"Yuting Fang, Binhao Wu, Rong Zhang, Xiaozhong Chen, Feng Jiang, Qifeng Jin, Ting Jin, Shuang Huang, Changjuan Tao, Mengyun Qiang, Yongfeng Piao, Yonghong Hua, Xinglai Feng, Caineng Cao","doi":"10.1097/CJI.0000000000000556","DOIUrl":"10.1097/CJI.0000000000000556","url":null,"abstract":"Immunotherapy combined with chemotherapy has become the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). However, the impact of antibiotic (ATB) use on the efficacy of immunotherapy in RM-NPC remains unclear. A total of 200 patients with RM-NPC who started first-line immunotherapy between October 2021 and September 2023 were included. Forty-six patients received ATB within 60 days before and 42 days after the first infusion of immunotherapy (group ATB+), and the remaining 154 patients were in group ATB-. The median progression-free survival (PFS) times of the ATB+ and ATB- groups were 11.20 and 19.87 months, respectively ( P = 0.061). The 2-year overall survival (OS) rates of the ATB+ and ATB- groups were 52.6% and 76.7%, respectively ( P = 0.001). In multivariate analysis, ATB use was significantly associated with worse OS (hazard ratio = 2.549, P = 0.002). No significant differences were observed between the 2 groups in terms of grade 3+ treatment-related adverse events. ATB use in RM-NPC may reduce the effectiveness of first-line immunotherapy.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"231-236"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of Immune Characteristics of 2 Subtypes of Breast Cancer by Combining Polyamine Metabolism-related Genes to Help With Immunotherapy. 联合多胺代谢相关基因帮助免疫治疗鉴定2种亚型乳腺癌的免疫特性

IF 3.2 4区医学

Journal of Immunotherapy Pub Date : 2025-07-01 Epub Date: 2025-04-30 DOI: 10.1097/CJI.0000000000000559

Xiuwen Yi, Bin Tang, Qinghua Mo, Yulan Tang, Wei Fu, Lingling Zhang, Liming Xie

{"title":"Identification of Immune Characteristics of 2 Subtypes of Breast Cancer by Combining Polyamine Metabolism-related Genes to Help With Immunotherapy.","authors":"Xiuwen Yi, Bin Tang, Qinghua Mo, Yulan Tang, Wei Fu, Lingling Zhang, Liming Xie","doi":"10.1097/CJI.0000000000000559","DOIUrl":"10.1097/CJI.0000000000000559","url":null,"abstract":"This project aims to explore the clustering value of polyamine metabolism-related genes (PMRGs) in breast cancer (BC) to assist treatment. ConsensusClusterPlus R package was employed to cluster BC patients based on the expression of PMRGs. Using the edgeR R package, we analyzed differentially expressed genes (DEGs) of different molecular clusters. Core genes were screened and enriched by the PPI network. Univariate COX was applied to determine genes tightly linked with survival. ConsensusClusterPlus R package was employed to cluster PMRGs. Differences in immune infiltration and expression of immune checkpoints between 2 subgroups were analyzed. Response to immunotherapy was assessed based on the expression level of immunophenoscore (IPS). Drug sensitivity of different PMRG clusters was assessed by pRRophitic R package. We clustered BC patients into 2 different subtypes with different survival rates and biological functions based on the expression of 16 PMRGs. Application of univariate COX analysis identified genes greatly associated with survival and divided BC patients into 2 different PMRG clusters. Patients in the 2 clusters exhibited differences in overall survival rate and immune cell infiltration levels, with multiple immune cells displaying higher immune levels in PMRG cluster 2. PMRG cluster 2 demonstrated higher expression of HLA and IC as well as IPS. Cluster 1 exhibited higher sensitivity to (5Z)-7-Oxozeaenol, 5-Fluorouracil, and 681640, while cluster 2 exhibited higher sensitivity to A-443654 and A-770041. We identified 2 clusters of PMRG with significant differences in the immune microenvironment in BC and predicted potential drugs, aiming to find new directions for clinical treatment of BC.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"209-220"},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0